The acquisition, which was announced in September 2012, met all requirements contained in the initial agreement between Bayer and Teva, and recently received the necessary regulatory approval from the Federal Trade Commission.

“This acquisition fits nicely with our strategic goals. It allows us to strengthen and broaden our range of animal care solutions in the U.S. market,” said Joerg Reinhardt, CEO, Bayer HealthCare.

Bayer HealthCare Animal Health’s food animal franchise will be strengthened with the addition of a range of anti-infective solutions to treat infections in livestock populations. It also introduces reproductive hormones such as Prostamate and Ovacyst to Bayer’s product offerings.

Bayer’s growing companion animal business is further enriched with the addition of dermatological, pet wellness and nutraceutical products.  end mark


—From Bayer HealthCare news release